Cprit Aml was Marker Therapeutics’s largest product and service line in fiscal 2025, bringing in $900.01K of $3.55M (25%).
| Product and Service | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cprit Grant | $3.40M | — | — | — | $2.70M | — | — | — | — | ||||
| Cprit Aml | — | — | — | — | — | — | — | $4.41M | $900.01K | ||||
| Related Party Service Revenue | — | $2.50M | — | — | — | — | — | — | — | ||||
| Sbir Pancreatic Cancer Grant | — | — | — | — | — | — | $2.00M | $7.18K | $425.67K | ||||
| Service Revenue | — | — | — | $800.00K | — | — | — | — | — | ||||
| National Institutes Of Health National - Cancer Institute Grant | — | — | — | — | — | $2.00M | — | $5.82K | $391.31K | ||||
| Sbir Lymphoma Grant | — | — | — | — | — | — | — | $665.00K | $665.00K | ||||
| Cprit Pancreatic Grant1 | — | — | — | — | — | — | — | — | $573.99K | ||||
| Grant Income | — | — | — | — | — | — | — | — | — | ||||
| Grant | — | — | — | — | — | — | — | — | — | ||||
| Sbir Aml | — | — | — | — | — | — | — | $982.18K | $472.21K | ||||
| National Institutes Of Health Small Business Innovation Research | — | — | $200.00K | — | $200.00K | — | — | — | — | ||||
| Fda Grant | $100.00K | — | — | — | $400.00K | — | — | $519.75K | $118.48K | ||||
| Total | $3.50M | $2.50M | $200.00K | $800.00K | $3.30M | $2.00M | $2.00M | $6.59M | $3.55M |
Marker Therapeutics brought in $3.55M from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. Marker Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $6.59M. Cprit Aml was the largest at $900.01K (25.4%), ahead of Sbir Lymphoma Grant at $665.00K (18.7%) and Cprit Pancreatic Grant1 at $573.99K (16.2%). The other four lines brought in $1.41M combined.
Compared with fiscal 2024, National Institutes Of Health National - Cancer Institute Grant grew fastest, up 6,621.1% to $391.31K, while Cprit Aml fell the most, down 79.6% to $900.01K.
Marker Therapeutics began breaking out Cprit Aml in fiscal 2024, Sbir Pancreatic Cancer Grant in fiscal 2024, National Institutes Of Health National - Cancer Institute Grant in fiscal 2024 and Sbir Lymphoma Grant in fiscal 2024. Marker Therapeutics stopped reporting Cprit Grant ($2.70M in fiscal 2023), Related Party Service Revenue ($2.50M in fiscal 2023), Service Revenue ($800.00K in fiscal 2023) and one other as separate lines.
Marker Therapeutics (MRKR) reports its revenue by product and service. In fiscal 2025, Cprit Aml was its largest product and service line, bringing in $900.01K (25.4% of the total), followed by Sbir Lymphoma Grant at $665.00K (18.7%).
Cprit Aml was Marker Therapeutics' largest product and service line in fiscal 2025, bringing in $900.01K, or 25.4% of the $3.55M total across its seven product and service lines.
Every figure comes from Marker Therapeutics' annual financial filings, as reported. Each line keeps the name Marker Therapeutics gives it, and years follow its fiscal calendar.
Marker Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.